CCL2 and thrombotic thrombocytopenic purpura: After excluding patients receiving immunosuppressive therapy (corticosteroids with/without rituximab) within 6 months prior to sampling from the analysis, we found that the observed differences in MCP-1 levels between TTP remission and acute TTP groups disappeared.